Literature DB >> 7865897

Decreased beta-endorphin content in peripheral blood mononuclear leukocytes from patients with Crohn's disease.

C J Wiedermann1, P Sacerdote, A Propst, T Propst, G Judmaier, H Kathrein, W Vogel, A E Panerai.   

Abstract

Increased activation of lymphocytes in inflammatory bowel disease is reflected by alterations of various immunological functions including enhanced spontaneous secretion of rheumatoid factor by mononuclear cells. since in rheumatic diseases increased secretion of rheumatoid factor is associated with decreased levels of beta-endorphin in circulating blood mononuclear leukocytes, we investigated levels of leukocyte beta-endorphin in inflammatory bowel disease and compared them with those in hepatobiliary disorders and in healthy subjects. Levels of beta-endorphin were measured in extracts from peripheral blood mononuclear leukocytes by radioimmunoassay. beta-Endorphin levels ranged from 0 to 67 pg/10(6) cells. Mononuclear leukocytes from ulcerative colitis patients contained as much beta-endorphin as those from healthy control subjects. In patients with Crohn's disease, levels of beta-endorphin were reduced by as much as roughly 50%. An inverse relationship was found between leukocyte beta-endorphin on the one hand and erythrocyte sedimentation rate, blood granulocyte or thrombocyte counts, and C-reactive protein levels in plasma on the other. In patients with various hepatobiliary disorders including fatty liver disease, viral hepatitis, primary biliary cirrhosis, and cryptogenic or alcoholic cirrhosis, beta-endorphin levels were not significantly different from the normal range values. Data indicate that leukocyte beta-endorphin may be involved in regulation of the systemic inflammatory activity of Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7865897     DOI: 10.1006/brbi.1994.1024

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  6 in total

1.  Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation.

Authors:  D Philippe; D Chakass; X Thuru; P Zerbib; A Tsicopoulos; K Geboes; P Bulois; M Breisse; H Vorng; J Gay; J-F Colombel; P Desreumaux; M Chamaillard
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

2.  Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines.

Authors:  P Sacerdote; V E di San Secondo; G Sirchia; B Manfredi; A E Panerai
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

3.  Low-dose naltrexone for pruritus in systemic sclerosis.

Authors:  Tracy Frech; Kirsten Novak; Monica P Revelo; Maureen Murtaugh; Boaz Markewitz; Nathan Hatton; Mary Beth Scholand; Edward Frech; David Markewitz; Allen D Sawitzke
Journal:  Int J Rheumatol       Date:  2011-09-12

4.  Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control.

Authors:  Daniel Kapitzke; Irina Vetter; Peter J Cabot
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

5.  Mechanisms Underlining Inflammatory Pain Sensitivity in Mice Selected for High and Low Stress-Induced Analgesia-The Role of Endocannabinoids and Microglia.

Authors:  Piotr Poznanski; Joanna Giebultowicz; Justyna Durdzinska; Tomasz Kocki; Mariusz Sacharczuk; Magdalena Bujalska-Zadrozny; Anna Lesniak
Journal:  Int J Mol Sci       Date:  2022-10-02       Impact factor: 6.208

6.  Basal Plasma Levels of Copeptin are Elevated in Inactive Inflammatory Bowel Disease after Bowel Resection.

Authors:  Bodil Ohlsson; Olle Melander
Journal:  Drug Target Insights       Date:  2015-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.